In the future, as we build capacity and grow we will begin offering treatment as regulations allow, which will include:
- MDMA-assisted psychotherapy for Posttraumatic Stress Disorder (PTSD)
- Psilocybin-assisted psychotherapy for end-of-life distress in people with a palliative diagnosis
- Psilocybin-assisted psychotherapy for treatment-resistant depression (TRD)
- Psilocybin-assisted psychotherapy for co-occurring substance use disorders and TRD and PTSD
Our faculty will also begin collecting safety and quality improvement data to inform future clinical programming. An early priority will be to treat vulnerable populations who are historically underrepresented in clinical trials, including refugees, members from BIPOC and LGBTQ+ communities and individuals from low socioeconomic backgrounds. We will also recruit therapists from these communities to participate in its training program.
More information will be available here when we are open to referrals.
To make a donation to support Psychedelic Psychotherapy Research, please visit the
UHN Foundation.
